ResMed to Host Its 2024 Investor Day on September 30, 2024, at the New York Stock Exchange
September 10, 2024 16:05 ET
|
ResMed Inc.
Learn more about ResMed’s 2030 strategy to accelerate growthJoin in person or via virtual webcast SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) will host an...
Vaping Expected to Increase COPD Health and Economic Burden by 2050
September 10, 2024 08:00 ET
|
ResMed Inc.
Vaping Expected to Increase COPD Health and Economic Burden by 2050
New ResMed-supported research presented at ERS 2024
ResMed Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 28, 2024 16:05 ET
|
ResMed Inc.
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will...
ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board
August 15, 2024 16:05 ET
|
ResMed Inc.
DelOrefice is the Chief Financial Officer at BD, one of the largest global MedTech companies in the worldBoard appointment brings over 30 years of strategic and operational finance expertise SAN...
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024
August 01, 2024 16:05 ET
|
ResMed Inc.
Year-over-year revenue grows 9%, operating profit up 38%, non-GAAP operating profit up 30%Operating cash flow of $440 millionQuarterly dividend increases 10% to $0.53 per shareCompany to host an...
ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
July 03, 2024 16:05 ET
|
ResMed Inc.
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2024 on...
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
June 10, 2024 09:05 ET
|
ResMed Inc.
ResMed-supported research presented at SLEEP2024 demonstrates the effectiveness and value of positive airway pressure (PAP) treatment for OSA.
Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
May 23, 2024 09:05 ET
|
ResMed Inc.
New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
May 16, 2024 16:35 ET
|
ResMed Inc.
ATS 2024: New ResMed-Supported Research Shows
Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
ResMed Announces Participation in the RBCCM Global Healthcare Conference
May 07, 2024 16:05 ET
|
ResMed Inc.
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Dr. Carlos Nunez, Chief Medical Officer, and Amy Wakeham, Chief Investor Relations Officer, will participate...